Regorafenib also inhibited tumor growth in a TH-MYCN transgenic NB mouse model, and regorafenib treatment resulted in dramatically improved survival of the TH-MYCN transgenic tumor-bearing mice. Here, MYCN is linked to neuroblastoma.